GCP
PRME icon

GSA Capital Partners’s Prime Medicine PRME Stock Holding History

GSA Capital Partners’s Portfolio PRME Stock Details PRME Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-38,510
Closed -$134K – 2074
2025
Q4 		$134K Buy
+38,510
New +$171K 0.01% 1495
2025
Q2 		– Sell
-153,273
Closed -$305K – 2070
2025
Q1 		$305K Buy
153,273
+137,962
+901% +$352K 0.03% 1139
2024
Q4 		$45K Sell
15,311
-83,749
-85% -$294K ﹤0.01% 1539
2024
Q3 		$383K Buy
+99,060
New +$459K 0.03% 1095
2024
Q1 		– Sell
-12,195
Closed -$108K – 1895
2023
Q4 		$108K Buy
+12,195
New +$94K 0.01% 1387

Other funds holding PRME

AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

GSA Capital Partners's PRME Position: Q1 2026 in Review

GSA Capital Partners sold out of Prime Medicine (PRME) in Q1 2026, closing a stake of 38,510 shares — an estimated $134K sold.

GSA Capital Partners first reported a position in PRME in Q4 2023 and held it in 5 quarters. The position peaked at $383K in Q3 2024. 192 funds tracked by Wall St. Rank hold PRME as of Q1 2026.

  • GSA Capital Partners reported no remaining Prime Medicine position as of Q1 2026 after selling out during the quarter.
  • GSA Capital Partners sold 38,510 Prime Medicine shares in Q1 2026, an estimated $134K.
  • GSA Capital Partners first reported a position in Prime Medicine in Q4 2023 and held it in 5 quarters.
  • GSA Capital Partners's Prime Medicine position peaked at $383K in Q3 2024.
  • 192 funds tracked by Wall St. Rank held Prime Medicine as of Q1 2026.

Based on GSA Capital Partners's 13F filing for Q1 2026, filed 8 May 2026.